[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasm-of-breast\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasm-of-breast":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100423455",false,"NCT04794075","Therapeutic Education and Nursing Support Program for Supportive Care, in Patients Treated With Hormone Therapy for Non-metastatic Breast Cancer","Programme d'Éducation Thérapeutique et d'Accompagnement Infirmier Vers Les Soins de Support, Chez Les Patientes Sous Hormonothérapie Pour un Cancer du Sein Non métastatique","ETAPH","Inclusion Criteria:\n\n* Female patients aged 18 to 75 years inclusive\n* Patients with non-metastatic breast cancer for whom adjuvant hormone therapy (anti-oestrogen or anti-aromatase) is indicated, depending on the decision of the multidisciplinary consultation meeting.\n* Performance status (ECOG) ≤ 2\n* Patient able to read and understand French (common use)\n* Patient with access to an internet connection (for collection of adverse events and responses to questionnaires on the electronic platform)\n* Patient who has been informed and has given written consent to participate in the study\n* Patient affiliated to the French social security system or equivalent\n\nExclusion Criteria:\n\n* Patient with metastatic cancer (stage IV)\n* Patient undergoing neoadjuvant hormone therapy\n* Patient who started hormone therapy prior to inclusion in the study\n* Patient with a history of other cancer treated by radiotherapy, chemotherapy or hormone therapy, with an end of treatment less than 2 years ago.\n* For patients in the experimental group: Inability of the patient to travel to the hospital to attend the initial assessment day and the proposed group outpatient workshops; follow-up of the program difficult for geographical, physical or other reasons (at the discretion of the investigator).\n* For patients in the control group: patients for whom telephone nursing follow-up is planned for 2 months or more or more than 4 sessions of therapeutic education.\n* Pregnant and breastfeeding women\n* Patient with a documented history of cognitive or psychiatric disorders\n* Refusal to participate, protected adult patient, under guardianship or curatorship","FEMALE","18 Years","75 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","To compare the efficacy of the addition of a therapeutic education program combined with nursing phone follow-up, compared to conventional management alone, on the management of adverse events (AEs) related to adjuvant hormone therapy during the first year of treatment in patients with non-metastatic breast cancer.",[27],"Neoplasm of Breast",[29,30,31,32,33],"Therapeutic Education","Nursing Support Program","Hormone Therapy","Non-metastatic Breast Cancer","Breast Cancer","RECRUITING","2025-07-30",{"date":37,"type":38},"2025-08-03","ACTUAL",{"date":40,"type":38},"2021-08-09",{"date":42,"type":21},"2027-08",{"name":44,"class":45},"Centre Hospitalier Emile Roux","OTHER",9,""]